Professor Dominic Behan
Professor Behan received his Ph.D. under Professor Phil Lowry at the University of Reading, that resulted in the purification of corticotropin releasing factor (CRF)-binding protein (CRF-BP), a key modulator of the CRF family of neuropeptides that are the principle mediators of the body's response to stress. The gene was subsequently cloned in collaboration with Professor Wylie Vale and colleagues at the Salk Institute in California. In 1997, Dr. Behan co-founded Arena Pharmaceuticals Inc., a company focused of discovering drugs targeting a broad class of signaling molecules called G-protein coupled receptors (GPCRs). Arena developed a robust pipeline of GPCR modulators, the first of which, BELVIQ® (lorcaserin HCl), was approved by the FDA in 2012 for chronic weight management. He now acts as Chair of the Arena Scientific Advisory Board, was included in the PharmaVOICE 100 list, serves on the scientific advisory board of Keystone and received a higher doctorate degree (D.Sc.) from the University of Reading where he was also appointed as Visiting Professor. Dr. Behan now serves as CEO of Sentia Medical Sciences Inc., a company whose vision is to bring to fruition several decades of academic research to achieve translational drug candidacy, by developing a new class of drug candidates called astressins for the treatment of stress-related diseases.